Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

In a major breakthrough for diabetes treatment, scientists have found a new way to regenerate insulin-producing cells. This ...

A recent medical trial could help deliver the first daily weight loss pill capable of cutting down obesity as effectively as ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Eli Lilly announced the results of a clinical trial for its new pill, which the company said causes nearly 8% weight loss at ...

The drugmaker Lilly announced topline results of a clinical trial of a new pill in the same drug class as injectables like ...

When it comes to managing weight loss and type 2 diabetes with medications, research shows that it's out with the old and in ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though ...

The data from more than 56 million pregnancies was reviewed to examine links between elevated glucose levels and mental ...